NEW YORK (Reuters Health)—Romosozumab shows smaller benefits for increasing bone mineral density (BMD) in the second year of treatment compared to the first, new research… [Read More]
Latest News
Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk
ACR/ARHP Members Call on Congress to Restore Patients’ Voices
HCV-Associated Cryoglobulinemic Vasculitis Resolves after Virologic Cure
Denosumab Is Effective for Glucocorticoid-Induced Osteoporosis
A study identified denosumab as a useful treatment for patients initiating or continuing glucocorticoids who are at risk for fractures. Denosumab had clinical effects similar to risedronate but was more effective than risedronate in the improvement of bone mineral density at the lumbar spine… [Read More]
ACR Program Encourages Innovation & Opportunity
With a steadily diversifying U.S. population, the professional and societal consequences of health disparities continue to grow. Rheumatologists may need to innovate to prevent these disparities for their patients. A new ACR program will focus on member-led projects that reduce health racial and ethnic disparities for patients with rheumatic disease… [Read More]
